COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out

Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.

Written byAsher Jones
| 2 min read
COVID-19, coronavirus, SARS-CoV-2, pandemic, virus, vaccine, vaccination, Pfizer, AstraZeneca

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, GEMPHOTOGRAPHY

New results from England- and Scotland-based studies suggest that the UK’s COVID-19 vaccination program is effective at reducing hospitalizations and the risk of contracting the disease.

Preliminary findings from a study of the Scottish population found that there were 85 percent fewer hospital admissions for people who received the first dose of the Pfizer/BioNTech vaccine four weeks prior compared with those who were unvaccinated. Similarly, one shot of Oxford/AstraZeneca’s version was tied to a reduction in hospitalizations of up 94 percent, according to the Associated Press. The results, which have not yet undergone peer review, were posted to The Lancet’s preprint site on February 19.

A second study, which was posted to The Lancet’s preprint site on February 22, of health care workers in England found that one shot of Pfizer’s vaccine was associated with a reduced risk of contracting the disease by 70 percent, while ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies